Allergy Therapeutics plc Stock OTC Markets
Stocks
AGYTF
GB00B02LCQ05
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
09:30:56 2026-07-02 EDT
|
5-day change | 1st Jan Change | ||
| 0.1500 USD | +7.14% |
|
-.--% | +36.36% |
| 07-30 | WINNERS & LOSERS: Vanquis cuts outlook; Zoo Digital loss narrows | AN |
| 07-29 | EARNINGS AND TRADING: Hargreaves Services results beat guidance | AN |
| Market Cap | 301M 407M 350M 332M 564M 38.86B 567M 3.94B 1.52B 19.77B 1.53B 1.49B 62.47B | P/E 2026 * |
-5.22x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 345M 467M 402M 381M 647M 44.57B 651M 4.52B 1.74B 22.68B 1.75B 1.71B 71.65B | EV / Sales 2026 * |
5.76x | EV / Sales 2027 * | - |
| Free-Float |
11.23% | Yield 2026 * |
-
| Yield 2027 * | - |
OTC MarketsUSD
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AGY | Delayed | |
OTC Markets
| AGYTF | Delayed | |
Deutsche Boerse AG
| HHU | Delayed | |
Börse Stuttgart
| HHU | Delayed | |
Boerse Muenchen
| HHU | Real-time |
| 1 day | +7.14% | ||
| 3 months | +15.38% | ||
| 6 months | +36.36% | ||
| Current year | +36.36% |
| Current year | 0.11 | 0.15 | |
| 1 year | 0.09 | 0.15 | |
| 3 years | 0.01 | 0.15 | |
| 5 years | 0.01 | 0.54 | |
| 10 years | 0 | 0.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Manuel Llobet
CEO | Chief Executive Officer | 62 | 2009-06-30 |
Shaun Furlong
DFI | Director of Finance/CFO | - | 2023-08-10 |
Matthias Kramer
PRN | Corporate Officer/Principal | - | 2013-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Manuel Llobet
BRD | Director/Board Member | 62 | 2009-06-10 |
Peter Jensen
CHM | Chairman | 75 | 2011-01-03 |
| Director/Board Member | 69 | 2017-06-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.14% | -.--% | - | - | 407M | ||
| -1.48% | -5.59% | +39.55% | -6.16% | 78.04B | ||
| +5.38% | -1.09% | +512.38% | +36.80% | 57.48B | ||
| -1.42% | -4.24% | -19.59% | -38.20% | 57.4B | ||
| -0.56% | -2.21% | -11.34% | +27.29% | 48.81B | ||
| +1.93% | -2.37% | -0.87% | +149.45% | 45.5B | ||
| +0.80% | -1.67% | +49.90% | -15.98% | 32.08B | ||
| -1.47% | -4.17% | +46.17% | +89.12% | 24.62B | ||
| -0.85% | -8.64% | -4.39% | +161.31% | 20.77B | ||
| -0.09% | -3.61% | +62.49% | +98.37% | 15.75B | ||
| Average | +0.94% | -3.87% | +74.92% | +55.78% | 42.27B | |
| Weighted average by Cap. | +0.38% | -3.71% | +90.55% | +37.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 59.9M 81.01M 69.79M 66.09M 112M 7.74B 113M 785M 302M 3.94B 304M 298M 12.44B | - |
| Net income | -55.7M -75.33M -64.9M -61.45M -104M -7.2B -105M -730M -281M -3.66B -283M -277M -11.57B | - |
| Net Debt | 44.2M 59.77M 51.5M 48.76M 82.92M 5.71B 83.34M 579M 223M 2.91B 224M 220M 9.18B | - |
Employees
584
Sector
Pharmaceuticals
Sell
Buy

Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0475GBP
Average target price
0.1300GBP
Spread / Average Target
+173.68%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AGY Stock
- AGYTF Stock
Select your edition
All financial news and data tailored to specific country editions

















